Exploring the Emerging Treatment Landscape of Relapsed/Refractory Diffuse Large B-Cell | PTCE Pharmacy Connect

Educational Objective:

• Outline various challenges and uncertainties affecting the optimization of treatment with novel immunotherapeutic modalities for relapsed/refractory diffuse large B-cell lymphoma.

 

Faculty:

Victoria Nachar, PharmD, BCOP

Clinical Pharmacist Specialist - Hematology

University of Michigan Rogel Cancer Center

Ann Arbor, Michigan

 

Moderator:

Laura R. Bobolts, PharmD, BCOP

SVP, Clinical Strategy and Growth

OncoHealth

Plantation, Florida

 

Victoria Nachar, PharmD, BCOP & Laura R. Bobolts, PharmD, BCOP, have no financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-22-611-H01-P. The activity is available for CE credit through December 22, 2023.

 

This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc; Genmab; and AbbVie, Inc.